California State Teachers Retirement System Sells 18,161 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

California State Teachers Retirement System cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 603,622 shares of the medical research company's stock after selling 18,161 shares during the quarter. California State Teachers Retirement System owned 0.16% of Thermo Fisher Scientific worth $314,022,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Howard Capital Management Group LLC grew its holdings in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after purchasing an additional 286 shares during the last quarter. Principal Financial Group Inc. increased its position in Thermo Fisher Scientific by 22.1% in the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after buying an additional 225,568 shares during the period. Virtu Financial LLC bought a new stake in Thermo Fisher Scientific in the third quarter valued at $638,000. Anchor Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 1.7% during the third quarter. Anchor Investment Management LLC now owns 11,366 shares of the medical research company's stock worth $7,031,000 after acquiring an additional 195 shares during the last quarter. Finally, World Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 15,088 shares of the medical research company's stock valued at $9,333,000 after purchasing an additional 548 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,200 shares of company stock valued at $13,235,041. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 2.1 %

Shares of TMO stock traded down $9.12 during trading on Thursday, hitting $419.88. 2,770,765 shares of the company were exchanged, compared to its average volume of 1,764,703. The firm has a market capitalization of $158.50 billion, a price-to-earnings ratio of 25.40, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The business's 50-day simple moving average is $480.79 and its 200 day simple moving average is $524.13. Thermo Fisher Scientific Inc. has a twelve month low of $409.85 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.11 earnings per share. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Analyst Upgrades and Downgrades

TMO has been the topic of several analyst reports. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Citigroup cut their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. StockNews.com downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, UBS Group lowered their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.